{
    "clinical_study": {
        "@rank": "115824", 
        "acronym": "FLAN", 
        "arm_group": [
            {
                "arm_group_label": "Fluoxetine", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will take 20 mg fluoxetine daily for 90 days starting at day 5-10 after stroke."
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will take one pill  daily for 90 days."
            }
        ], 
        "brief_summary": {
            "textblock": "This pilot study will recruit 16-25 subjects  to assess the feasibility of replicating the\n      FLAME study (Chollet, et al. Lancet 2011), an randomized controlled trial (RCT) that\n      assessed the effect of fluoxetine vs placebo on motor recovery after ischemic stroke,  in an\n      American sample of post-acute stroke patients. This trial will in addition examine the\n      effect of treatment with fluoxetine versus placebo on concurrent deficits in language and\n      hemispatial attention, and will evaluate the durability of observed effects in all 3\n      domains. The results of this pilot trial will be used to develop power estimates for a\n      larger trial and to evaluate recruitment and intervention completion rates for subjects in\n      an American post-acute environment."
        }, 
        "brief_title": "Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 and older\n\n          -  Ischemic infarction within the past 10 days\n\n          -  Fluent in English\n\n          -  May require assistance of surrogate to give consent\n\n          -  Functional Communication Measure >=1 for patients with inattention\n\n          -  Functional Communication Measure >=3 for patients with aphasia\n\n          -  NIH Stroke Scale < 20 on admission to Spaulding\n\n          -  Able to follow directions and participate in 2 hrs of testing with short breaks\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating\n\n          -  Hemianopsia\n\n          -  Active depression on admission to Spaulding\n\n          -  Taking an SSRI or other medication likely to have adverse interaction with an SSRI\n\n          -  Resides too far away to return for follow-up testing\n\n          -  Unable to give consent and no surrogate available"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01674868", 
            "org_study_id": "FLAN SpauldingRH"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fluoxetine", 
                "description": "20 mg daily for 90 days starting day 5-10 after stroke.", 
                "intervention_name": "fluoxetine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "subjects will take one pill po daily for 90 days.", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fluoxetine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "stroke", 
            "recovery", 
            "fluoxetine", 
            "aphasia", 
            "neglect", 
            "motor"
        ], 
        "lastchanged_date": "April 5, 2013", 
        "location": {
            "contact": {
                "email": "rblackschaffer@partners.org", 
                "last_name": "Randie Black-Schaffer, MD", 
                "phone": "617-573-7106"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Spaulding Rehabilitation Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Yong-Tae Lee, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Nicole Mazwi, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pilot RCT of Fluoxetine vs Placebo to Treat Motor, Language and Unilateral Neglect After Ischemic Stroke", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "change in FMMS", 
                "measure": "Fugl-Meyer Motor Scale (FMMS)", 
                "safety_issue": "No", 
                "time_frame": "baseline to 45 days"
            }, 
            {
                "description": "change in FMMS score", 
                "measure": "Fugl-Meyer Motor Scale (FMMS)", 
                "safety_issue": "No", 
                "time_frame": "baseline to 90 days"
            }, 
            {
                "description": "change in FMMS", 
                "measure": "Fugl-Meyer Motor Scale (FMMS)", 
                "safety_issue": "No", 
                "time_frame": "baseline to 180 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01674868"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Spaulding Rehabilitation Hospital", 
            "investigator_full_name": "Randie Black-Schaffer MD", 
            "investigator_title": "Medical Director, Stroke Program", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "change in Western Aphasia Quotient", 
                "measure": "Western Aphasia Battery", 
                "safety_issue": "No", 
                "time_frame": "baseline to 45 days"
            }, 
            {
                "description": "change in Western Aphasia Quotient", 
                "measure": "Western Aphasia Battery", 
                "safety_issue": "No", 
                "time_frame": "baseline to 90 days"
            }, 
            {
                "description": "change in Wester Aphasia Quotient", 
                "measure": "Western Aphasia Battery", 
                "safety_issue": "No", 
                "time_frame": "baseline to 90 days"
            }, 
            {
                "description": "change in BIT", 
                "measure": "Behavioral Inattention Test (BIT)", 
                "safety_issue": "No", 
                "time_frame": "baseline to 45 days"
            }, 
            {
                "description": "change in BIT", 
                "measure": "Behavioral Inattention Test (BIT)", 
                "safety_issue": "No", 
                "time_frame": "baseline to 90 days"
            }, 
            {
                "description": "change in BIT", 
                "measure": "Behavioral Inattention Test (BIT)", 
                "safety_issue": "No", 
                "time_frame": "baseline to 180 days"
            }, 
            {
                "description": "change in FIM", 
                "measure": "Functional Independence Measure", 
                "safety_issue": "No", 
                "time_frame": "baseline to discharge"
            }
        ], 
        "source": "Spaulding Rehabilitation Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spaulding Rehabilitation Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}